Octreotide ER is under clinical development by Debiopharm International and currently in Phase II for Acromegaly. According to GlobalData, Phase II drugs for Acromegaly have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Octreotide ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Octreotide ER overview

Octreotide ER (Debio-4126) is under development for the treatment of gastro-enteropancreatic neuroendocrine tumors and acromegaly. It is a sustained release formulation. The therapeutic candidate acts by targeting somatostatin receptor (SSTR). It is administered through intramuscular route and It is being developed based on modified-release Debiosphere technology. 

Debiopharm International overview

Debiopharm International, a subsidiary of Apes-demain SA focuses on the development and manufacture of drugs for oncology and bacterial infections. it offers complete treatment to the patients from diagnostics to treatment monitoring. The company offers oxaliplatin and triptorelin drugs. It is investigating proteins, peptides and small molecules to treat cancers, solid tumors, bone and joint infections and gastrointestinal disorders. Debiopharm is headquartered in Lausanne, Switzerland.

For a complete picture of Octreotide ER’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.